Elorac, Inc. Announces Orphan Designation in Europe for Novel Topical Treatment for Cutaneous T-Cell Lymphoma (CTCL)
Published: Nov 16, 2012
CHICAGO--(BUSINESS WIRE)--Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced that the European Medicines Agency (EMA) has designated Naloxone hydrochloride dehydrate as an orphan medicinal product under Regulation (EC) No. 141/2000 of the European Parliament and of the Council. Naloxone hydrochloride dehydrate is designated as an orphan medicinal product for the indication: Treatment of cutaneous T-cell lymphoma (CTCL). This designation, which was granted to Elorac’s European subsidiary, is entered in the Community Register of Orphan Medicinal Products under the number EU/3/12/1057.